Skip to main content
NewslettersWatchlist

Incyte Corp(INCY-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low79.53
Day High82.97
Open:81.00
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
GlobeNewswire
Knight Therapeutics Announces Approval of Minjuvi® (tafasitamab) in Mexico
Newswire.ca
Optimism Grows in the Fight Against Cancer as Breakthroughs and Funding Increase
Barchart
S&P 500 Falls from a Record High on Hawkish Powell
Barchart
Stocks Jolted By Fed's 50-Basis Point Rate Cut
Barchart
Stocks Slightly Higher Before FOMC Decision
Barchart
Tech Stocks Close Lower on Weakness in Apple and Chip Stocks
Barchart
Stocks Post Moderate Gains as Powell Says Inflation is Receding
Barchart
Stocks Mixed on Dovish Powell and Strong US Labor News
Barchart
Stocks Slip on Carryover Weakness in European Stocks
Barchart
Stock Index Futures Slip Ahead of U.S. JOLTs Report and Powell’s Remarks
Barchart
Stock Index Futures Tread Water Ahead of Key U.S. PPI Data and Powell Remarks
Barchart
Stocks Close Little Changed on Caution Ahead of US Inflation Reports
Barchart
Stocks Slightly Higher Ahead of This Week’s US Inflation Reports
Barchart
Stocks Climb on Lower Bond Yields and Positive Corporate News
GlobeNewswire
Knight Therapeutics Announces Launch of Minjuvi® in Brazil
Barchart
Stock Indexes Climb to Record Highs on a Tech Fueled Rally
Barchart
Stocks Slump as Hot U.S. CPI Report Dashes Fed Rate Cut Hopes
BayStreet.ca
Innovative Strategies in the Fight Against Pancreatic Cancer: A 2023 Recap
BayStreet.ca
The Fight Against Pancreatic Cancer Just Gained a New Ally with $200M VC Firm
GlobeNewswire
Knight Therapeutics Announces CMED Price Approval of Minjuvi® (tafasitamab) in Brazil
GlobeNewswire
Knight Therapeutics Announces Regulatory Submission of Pemigatinib in Brazil
MarketBeat
Argenx's 28% Surge & Promising Product Propel Investor Confidence

Profile

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. The company conducts its European clinical development operations in Geneva, Switzerland. Incyte's lead drug, Jakafi (ruxolitinib), is a first-in-class JAK1/JAK2 inhibitor, approved in the United States for the treatment of patients with polycythemia vera ('PV'),who have had an inadequate response to or are intolerant to hydroxyurea. It is also approved for the treatment of patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-PV MF, and post-essential thrombocythemia MF. The drug is also approved in the United States for treatment of steroid-refractory acute graft-versus-host disease (GVHD) in adult and pediatric patients aged 12 years or older.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.